New Drug Therapies for Multiple Myeloma
Multiple myeloma treatment continues to advance rapidly. New therapies now target the disease more precisely and produce deeper responses. As a result, options for both newly diagnosed and relapsed patients have expanded significantly.
First, bispecific antibodies have transformed care. These drugs engage T cells to attack myeloma cells. Teclistamab targets BCMA, while talquetamab targets GPRC5D. Elranatamab and linvoseltamab provide additional BCMA-directed choices. In March 2026, the FDA approved teclistamab plus daratumumab for patients who have received at least one prior line of therapy. The combination showed strong progression-free survival benefits in the MajesTEC-3 trial. Furthermore, dual bispecific approaches, such as teclistamab plus talquetamab, have demonstrated even deeper responses in earlier-relapse settings by reducing the risk of progression substantially.
Next, CAR T-cell therapies continue to improve outcomes. Ciltacabtagene autoleucel and idecabtagene vicleucel remain key options for relapsed disease. These therapies produce high response rates and durable remissions in many patients. Researchers are now testing them earlier in the treatment course. In addition, next-generation and in vivo CAR T approaches are under study. These aim to shorten manufacturing time and improve access.
Antibody-drug conjugates have also returned to the clinic. Belantamab mafodotin, combined with bortezomib and dexamethasone, received FDA approval in 2025 for patients after at least two prior lines. The regimen improved both progression-free and overall survival compared with standard options. However, ocular toxicity requires careful monitoring through a risk management program.
Meanwhile, a new class of drugs has entered practice. Iberdomide, the first cereblon E3 ligase modulator, gained accelerated approval in August 2026 in combination with daratumumab and dexamethasone. It produced higher rates of minimal residual disease–negative complete responses than older regimens. Quadruplet regimens that include anti-CD38 antibodies have also become standard for newly diagnosed patients, regardless of transplant eligibility. Subcutaneous formulations of isatuximab and daratumumab further improve convenience.
Finally, treatment is shifting earlier. Daratumumab monotherapy is now approved for high-risk smoldering multiple myeloma to delay progression. Combinations of bispecific antibodies are moving into frontline and early-relapse settings. These changes offer the possibility of deeper and more durable control for many patients. Ongoing trials continue to refine sequencing, manage side effects such as infections and cytokine release syndrome, and expand access to these therapies.